# ASIS for Botox in Chronic Migraine

> **NCT02074163** · PHASE1,PHASE2 · UNKNOWN · sponsor: **ASIS Corporation** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.

## Interventions

- **DRUG:** Gadolinium
- **DRUG:** Gadolinium
- **DRUG:** Efficacy of Botox intramuscularly at Week 6
- **DRUG:** Efficacy of Botox intramuscularly at Week 12
- **DRUG:** Efficacy of Botox intramuscularly at Week 18
- **DRUG:** Efficacy of Botox intramuscularly at Week 24,
- **DRUG:** Efficacy of Botox intramuscularly at Week 30
- **DRUG:** Efficacy of Botox subdermally at Week 6
- **DRUG:** Efficacy of Botox subdermally at Week 12
- **DRUG:** Efficacy of Botox subdermally at Week 18
- **DRUG:** Efficacy of Botox subdermally at Week 24
- **DRUG:** Efficacy of Botox subdermally at Week 30
- **DRUG:** Adverse Reactions of Botox intramuscularly
- **DRUG:** Adverse Reactions of Botox subdermally

## Key facts

- **NCT ID:** NCT02074163
- **Lead sponsor:** ASIS Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2016-06
- **Final completion:** 2017-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02074163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02074163, "ASIS for Botox in Chronic Migraine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02074163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*